Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'Stranger Things' Season 5: When does Volume 2 come out? And Volume 3? Everything to know about the remaining episodes before the finale. - 2Top Smoothie Flavor: What's Your Mix?
- 3Like many holiday traditions, lighting candles and fireplaces is best done in moderation
- 4Alleged maple syrup scam in Quebec uncovered by Canadian broadcaster
- 5Paul Feig loves a plot twist. Why not reboot 'Die Hard' starring a woman?
- Analysis-From 'Icarus bug' to flawed panels: Airbus counts cost of relying on single model
- Meet the astronauts about to make history on flight around the moon
- Barry Manilow reveals lung cancer diagnosis and plans to undergo surgery: 'It's pure luck' it was 'found so early'
- Why are malnutrition deaths soaring in America?
- What's A Decent FICO rating?
- Collins Foods to offload 20 Taco Bell outlets in Australia
- See the first close-up photos of the moon from NASA's Artemis II mission
- 2024 Moving Styles for Kitchen Redesigns
- Trump administration plan to reduce access to some student loans angers nurses, health care groups
